How anyone can watch that Crux interview and not feel great about being a holder I have no idea. As others said, every answer was locked and loaded, and Dave looked so happy and confident, lots of smiles and quite a few smirks to some pointed Qs.
I said on my first HC post that out of my 8 stock precious metals mining stocks "this is the one I would recommend to my mother in law" and I stand by that, I mean that in a positive way too cause my mother in law is actually a legendRisk v Reward this is a brilliant play, I cant think of a lower risk play that has a better chance of doubling or tripling in the next 12-18 months.
Interview main point takeaways:
1. Dave re Macquarie as a funding choice - "Macquarie is a standout for us", "overall cost wise compelling", "We think Macquarie is a gold standard in funding"
2. The flexible terms of the funding are an important factor. No payments until 15 months after first drawdown (Q2 2021) , facility payout in 3.5 yrs after that, but in between can pay down quicker and also redraw. Dave mentioned the development of Blue spec, and resource expansion, as a use of redraw funds.
3. Dave re Blue spec "very excited about the deposit" but parking it to the side a little whilst they handle the immediate mine construction. They are working well with Novo who are like their next door neighbors.
4. Confirm they will be doing a capital raise because the Macquarie debt and cash on hand wont cover everything (as has been correctly forecast but some other contributors already on this forum).
5. Only Xmas - New Yr off otherwise going flat out
- Forums
- ASX - By Stock
- CAI
- Ann: CALIDUS SECURES $110 MILLION DEBT FINANCING FOR WARRAWOONA
Ann: CALIDUS SECURES $110 MILLION DEBT FINANCING FOR WARRAWOONA, page-43
-
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CAI (ASX) to my watchlist
|
|||||
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CAI (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online